利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.032 秒)

    DETERMINATION OF IMMUNOGENIC PEPTIDES IN LYSOSOMAL ENZYMES AND INDUCTION OF ORAL TOLERANCE
    2.
    发明申请
    DETERMINATION OF IMMUNOGENIC PEPTIDES IN LYSOSOMAL ENZYMES AND INDUCTION OF ORAL TOLERANCE 审中-公开
    肉毒杆菌中免疫球蛋白的测定和口服耐受性的诱导

    公开(公告)号：US20130202633A1

    公开(公告)日：2013-08-08

    申请号：US13760907

    申请日：2013-02-06

    申请人： Saint Louis University, a non-profit organization

    发明人： Adriana Montaño-Suarez ,  Angela Sosa-Molano ,  Alan Knutsen ,  Clifford Bellone ,  Shunji Tomatsu ,  Luis Barrera

    IPC分类号： C12N9/16

    CPC分类号： C12N9/16 ,  A61K39/001 ,  A61K2039/542 ,  C12Y301/06004

    摘要： Disclosed are methods and compositions for determining immunodominant peptides of target enzymes used in enzyme replacement therapy for lysosomal storage disorders. More specifically disclosed are immunodominant peptides for N-acetylgalactosamine-6-sulfatase (GALNS). Also disclosed are methods of inducing oral tolerance towards a target enzyme through oral administration of immunodominant peptides prior to commencing enzyme replacement therapy. More specifically disclosed is a method of inducing oral tolerance for GALNS, by orally administering specific immunodominant peptides for GALNS; in subjects suffering from mucopolysaccharidosis type IVA prior to commencing enzyme replacement therapy using GALNS.

    摘要翻译： 公开了用于确定用于溶酶体储存障碍的酶替代疗法中的靶酶的免疫显性肽的方法和组合物。 更具体地公开了N-乙酰半乳糖胺-6-硫酸酯酶（GALNS）的免疫显性肽。 还公开了在开始酶替代治疗之前通过口服施用免疫显性肽来诱导对靶酶的口服耐受性的方法。 更具体地公开了通过口服给予GALNS的特异性免疫显性肽来诱导GALNS的口服耐受性的方法; 在使用GALNS进行酶替代治疗之前，患有IVA型粘多糖症的受试者。

    MANUFACTURE OF ACTIVE HIGHLY PHOSPHORYLATED HUMAN N-ACETYLGALACTOSAMINE-6-SULFATASE AND USES THEREOF
    3.
    发明申请
    MANUFACTURE OF ACTIVE HIGHLY PHOSPHORYLATED HUMAN N-ACETYLGALACTOSAMINE-6-SULFATASE AND USES THEREOF 有权
    活性高磷酸化人乙酰胆碱酯酶6硫酸酯的制备及其用途

    公开(公告)号：US20140341878A1

    公开(公告)日：2014-11-20

    申请号：US14281538

    申请日：2014-05-19

    申请人： BioMarin Pharmaceutical Inc.

    发明人： Vish Koppaka ,  Michel Claude Vellard ,  Augustus Okhamafe ,  Kidisti Araya

    IPC分类号： C12N9/16

    CPC分类号： C12N9/16 ,  A61K9/08 ,  A61K38/00 ,  A61K38/465 ,  C12Y301/06004

    摘要： This invention provides compositions of active highly phosphorylated human N-acetylgalactosamine-6-sulfatase (GALNS), and pharmaceutical compositions and formulations thereof, methods of producing and purifying GALNS, and its use in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly lysosomal storage diseases that are caused by, or associated with, a deficiency in the GALNS enzyme, e.g., Mucopolysaccharidosis IVa (MPS IVa or Morquio A syndrome).

    摘要翻译： 本发明提供活性高度磷酸化的人N-乙酰半乳糖胺-6-硫酸酯酶（GALNS）的组合物及其药物组合物及其制剂，制备和纯化GALNS的方法及其在疾病和病症的诊断，预防或治疗中的用途， 包括特别是由GALNS酶的缺陷引起或与之相关的溶酶体贮积病，例如粘多糖贮积症IVa（MPS IVa或Morquio A综合征）。

    Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
    4.
    发明授权
    Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor 失效
    通过施用特异性硫酸酯酶和/或硫酸化抑制剂来治疗炎症

    公开(公告)号：US5925349A

    公开(公告)日：1999-07-20

    申请号：US916766

    申请日：1997-08-19

    申请人： Steven D. Rosen ,  Stefan Hemmerich ,  Yasuyuki Imai

    发明人： Steven D. Rosen ,  Stefan Hemmerich ,  Yasuyuki Imai

    IPC分类号： A61K38/45 ,  A61K38/46 ,  A61P29/00 ,  A61K38/47 ,  A61K33/04 ,  A61K33/20 ,  A61K38/43

    CPC分类号： A61K38/465 ,  C12Y301/06004

    摘要： Compositions are administered to a patient (preferably by injection and locally) to treat a variety of conditions including inflammation associated with trauma and with certain aspects of diseases such as rheumatoid arthritis, psoriasis, insulin-dependent diabetes, cutaneous lymphomas, duodenal ulcer, chronic proctitis, lymphocytic thyroiditis, hemorphagic shock, reperfusion injury during transplantation and multiple sclerosis. The compositions are pharmaceutically acceptable injectable formulations which include an active component in a pharmaceutically acceptable carrier. The active component is a chlorate or selenate which inhibits the natural biochemical sulfation process and/or a sulfatase enzyme which removes a sulfate from a specific position of a saccharide molecule which makes up a part of a natural ligand for L-selectin. Removal of the sulfate from the ligand hinders the ability of the ligand to bind to its natural receptor (i.e. L-selectin) and thereby hinders a biochemical chain of events which results in inflammation.

    摘要翻译： 将组合物施用于患者（优选通过注射和局部施用）以治疗包括与创伤相关的炎症以及诸如类风湿性关节炎，牛皮癣，胰岛素依赖性糖尿病，皮肤淋巴瘤，十二指肠溃疡，慢性直肠炎等疾病的某些方面的各种病症 ，淋巴细胞性甲状腺炎，血管性休克，移植期间的再灌注损伤和多发性硬化。 该组合物是药学上可接受的可注射制剂，其包括药学上可接受的载体中的活性成分。 活性组分是氯化物或硒酸盐，其抑制天然生化硫酸化过程和/或硫酸酯酶，其从构成L-选择素的天然配体的一部分的糖分子的特定位置去除硫酸盐。 从配体中除去硫酸盐阻碍配体结合其天然受体（即L-选择蛋白）的能力，从而阻碍导致炎症的事件的生物化学链。

    Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
    5.
    发明授权
    Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor 失效
    通过施用特异性硫酸酯酶和/或硫酸化抑制剂来治疗炎症

    公开(公告)号：US5695752A

    公开(公告)日：1997-12-09

    申请号：US496857

    申请日：1995-06-30

    申请人： Steven D. Rosen ,  Stefan Hemmerich ,  Yasuyuki Imai

    发明人： Steven D. Rosen ,  Stefan Hemmerich ,  Yasuyuki Imai

    IPC分类号： A61K38/45 ,  A61K38/46 ,  A61P29/00 ,  A61K38/47 ,  A61K38/43 ,  C12N9/24

    CPC分类号： A61K38/465 ,  C12Y301/06004

    摘要： Compositions are administered to a patient (preferably by injection and locally) to treat a variety of conditions including inflammation associated with trauma and with certain aspects of diseases such as rheumatoid arthritis, psoriasis, insulin-dependent diabetes, cutaneous lymphomas, duodenal ulcer, chronic proctitis, lymphocytic thyroidiris, hemorphagic shock, reperfusion injury during transplantation and multiple sclerosis. The compositions are pharmaceutically acceptable injectable formulations which include an active component in a pharmaceutically acceptable carrier. The active component is a chlorate or selenate which inhibits the natural biochemical sulfation process and/or a sulfatase enzyme which removes a sulfate from a specific position of a saccharide molecule which makes up a part of a natural ligand for L-selectin. Removal of the sulfate from the ligand hinders the ability of the ligand to bind to its natural receptor (i.e. L-selectin) and thereby hinders a biochemical chain of events which results in inflammation.

    摘要翻译： 将组合物施用于患者（优选通过注射和局部施用）以治疗包括与创伤相关的炎症以及诸如类风湿性关节炎，牛皮癣，胰岛素依赖性糖尿病，皮肤淋巴瘤，十二指肠溃疡，慢性直肠炎等疾病的某些方面的各种病症 ，淋巴细胞性甲状腺炎，血管性休克，移植期间的再灌注损伤和多发性硬化。 该组合物是药学上可接受的可注射制剂，其包括药学上可接受的载体中的活性成分。 活性组分是氯化物或硒酸盐，其抑制天然生化硫酸化过程和/或硫酸酯酶，其从构成L-选择素的天然配体的一部分的糖分子的特定位置去除硫酸盐。 从配体中除去硫酸盐阻碍配体结合其天然受体（即L-选择蛋白）的能力，从而阻碍导致炎症的事件的生物化学链。

    Manufacture of Active Highly Phosphorylated Human N-Acetylgalactosamine-6-Sulfatase and Uses Thereof
    8.
    发明申请
    Manufacture of Active Highly Phosphorylated Human N-Acetylgalactosamine-6-Sulfatase and Uses Thereof 有权
    活性高度磷酸化人类N-乙酰半乳糖胺-6-磺酸酯酶的制备及其用途

    公开(公告)号：US20160186149A1

    公开(公告)日：2016-06-30

    申请号：US14573907

    申请日：2014-12-17

    申请人： BioMarin Pharmaceutical Inc.

    发明人： Vish Koppaka ,  Michel Claude Vellard ,  Augustus O. Okhamafe ,  Kidisti Araya

    IPC分类号： C12N9/16 ,  A61K9/08 ,  A61K38/46

    CPC分类号： C12N9/16 ,  A61K9/08 ,  A61K38/00 ,  A61K38/465 ,  C12Y301/06004

    摘要： This invention provides compositions of active highly phosphorylated human N-acetylgalactosamine-6-sulfatase (GALNS), and pharmaceutical compositions and formulations thereof, methods of producing and purifying GALNS, and its use in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly lysosomal storage diseases that are caused by, or associated with, a deficiency in the GALNS enzyme, e.g., Mucopolysaccharidosis IVa (MPS IVa or Morquio A syndrome).

    摘要翻译： 本发明提供活性高度磷酸化的人N-乙酰半乳糖胺-6-硫酸酯酶（GALNS）的组合物及其药物组合物及其制剂，制备和纯化GALNS的方法及其在疾病和病症的诊断，预防或治疗中的用途， 包括特别是由GALNS酶的缺陷引起或与之相关的溶酶体贮积病，例如粘多糖贮积症IVa（MPS IVa或Morquio A综合征）。

    Chondrosulphatase and use thereof
    10.
    发明授权
    Chondrosulphatase and use thereof 有权

    公开(公告)号：US11667901B2

    公开(公告)日：2023-06-06

    申请号：US17601080

    申请日：2019-09-18

    申请人： NANJING HANXIN PHARMACEUTICAL INC

    发明人： Haoning Zhang ,  Song Chen ,  Chuangen Tang ,  Jing Wang

    IPC分类号： C12N9/16

    CPC分类号： C12N9/16 ,  C12Y301/06004

    摘要： Provided are chondrosulfatase and a use thereof, belonging to the technical field of biological engineering. Chondrosulfatase is screened and identified from the natural world, the maximum similarity between its amino acid sequence and that of the chondrosulfatase reported by NCBI being 85%; then the expression in Escherichia coli and Bacillus subtilis is optimized, achieving the high-efficiency biosynthesis of chondrosulfatase having high enzymatic activity, the maximum enzyme activity being 11976.5 U/L; furthermore, the entire process and post-processing are simpler. The invention has potentially broad value in application in the preparation of products containing low molecular-weight chondroitin sulfate in the fields of medicine, cosmetics, and biology, lays the foundation for efficient fermentation of a microbial system to produce a chondrosulfatase having high enzyme activity, and is suitable for industrialized production applications.